139 related articles for article (PubMed ID: 15065568)
1. Danger, death and DNA vaccines.
Bergmann-Leitner ES; Leitner WW
Microbes Infect; 2004 Mar; 6(3):319-27. PubMed ID: 15065568
[TBL] [Abstract][Full Text] [Related]
2. Adjuvants may reduce in vivo transfection levels for DNA vaccination in mice leading to reduced antigen-specific CD8+ T cell responses.
Rose AH; Hoffmann FW; Hara JH; Urschitz J; Moisyadi S; Hoffmann PR; Bertino P
Hum Vaccin Immunother; 2015; 11(9):2305-11. PubMed ID: 26091088
[TBL] [Abstract][Full Text] [Related]
3. Induction of HIV-1-specific cellular and humoral immune responses following immunization with HIV-DNA adjuvanted with activated apoptotic lymphocytes.
Brave A; Johansson U; Hallengärd D; Heidari S; Gullberg H; Wahren B; Hinkula J; Spetz AL
Vaccine; 2010 Feb; 28(9):2080-7. PubMed ID: 20044053
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo programming of antigen-presenting B lymphocytes: considerations on DNA uptake and cell activation.
Wheeler M; Cortez-Gonzalez X; Frazzi R; Zanetti M
Int Rev Immunol; 2006; 25(3-4):83-97. PubMed ID: 16818366
[TBL] [Abstract][Full Text] [Related]
5. Novel vaccines: bridging research, development and production.
Demirjian A; Levy O
Expert Rev Vaccines; 2008 Nov; 7(9):1321-4. PubMed ID: 18980535
[TBL] [Abstract][Full Text] [Related]
6. Improving vaccines by incorporating immunological coadjuvants.
Fraser CK; Diener KR; Brown MP; Hayball JD
Expert Rev Vaccines; 2007 Aug; 6(4):559-78. PubMed ID: 17669010
[TBL] [Abstract][Full Text] [Related]
7. Plasmid DNA vaccines.
Abdelnoor AM
Curr Drug Targets Immune Endocr Metabol Disord; 2001 May; 1(1):79-92. PubMed ID: 12476783
[TBL] [Abstract][Full Text] [Related]
8. Microparticles for the delivery of DNA vaccines.
O'Hagan DT; Singh M; Ulmer JB
Immunol Rev; 2004 Jun; 199():191-200. PubMed ID: 15233735
[TBL] [Abstract][Full Text] [Related]
9. CpG DNA as a Th1 trigger.
Heeg K; Zimmermann S
Int Arch Allergy Immunol; 2000 Feb; 121(2):87-97. PubMed ID: 10705218
[TBL] [Abstract][Full Text] [Related]
10. A KALA-modified lipid nanoparticle containing CpG-free plasmid DNA as a potential DNA vaccine carrier for antigen presentation and as an immune-stimulative adjuvant.
Miura N; Shaheen SM; Akita H; Nakamura T; Harashima H
Nucleic Acids Res; 2015 Feb; 43(3):1317-31. PubMed ID: 25605799
[TBL] [Abstract][Full Text] [Related]
11. Molecular adjuvants for malaria DNA vaccines based on the modulation of host-cell apoptosis.
Bergmann-Leitner ES; Leitner WW; Duncan EH; Savranskaya T; Angov E
Vaccine; 2009 Sep; 27(41):5700-8. PubMed ID: 19576940
[TBL] [Abstract][Full Text] [Related]
12. Use of CpG oligodeoxynucleotides as immune adjuvants.
Klinman DM; Currie D; Gursel I; Verthelyi D
Immunol Rev; 2004 Jun; 199():201-16. PubMed ID: 15233736
[TBL] [Abstract][Full Text] [Related]
13. DNA vaccines for prostate cancer.
Zahm CD; Colluru VT; McNeel DG
Pharmacol Ther; 2017 Jun; 174():27-42. PubMed ID: 28185916
[TBL] [Abstract][Full Text] [Related]
14. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice.
Moore AC; Kong WP; Chakrabarti BK; Nabel GJ
J Virol; 2002 Jan; 76(1):243-50. PubMed ID: 11739689
[TBL] [Abstract][Full Text] [Related]
15. Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity.
Kowalczyk A; Doener F; Zanzinger K; Noth J; Baumhof P; Fotin-Mleczek M; Heidenreich R
Vaccine; 2016 Jul; 34(33):3882-93. PubMed ID: 27269061
[TBL] [Abstract][Full Text] [Related]
16. Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy.
Rosato A; Zoso A; Milan G; Macino B; Dalla Santa S; Tosello V; Di Carlo E; Musiani P; Whalen RG; Zanovello P
J Immunol; 2003 Nov; 171(10):5172-9. PubMed ID: 14607917
[TBL] [Abstract][Full Text] [Related]
17. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant.
Zhang Y; Jiang W; Fan Y; Wen J; Hao W; Qian M
J Virol Methods; 2008 Nov; 153(2):142-8. PubMed ID: 18722475
[TBL] [Abstract][Full Text] [Related]
18. Improving DNA vaccine potency via modification of professional antigen presenting cells.
Hung CF; Wu TC
Curr Opin Mol Ther; 2003 Feb; 5(1):20-4. PubMed ID: 12669466
[TBL] [Abstract][Full Text] [Related]
19. Genetic adjuvants for DNA vaccines.
Scheerlinck JY
Vaccine; 2001 Mar; 19(17-19):2647-56. PubMed ID: 11257404
[TBL] [Abstract][Full Text] [Related]
20. In vivo electroporation enhances the potency of poly-lactide co-glycolide (PLG) plasmid DNA immunization.
Barbon CM; Baker L; Lajoie C; Ramstedt U; Hedley ML; Luby TM
Vaccine; 2010 Nov; 28(50):7852-64. PubMed ID: 20943208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
